Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
- NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
- NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_assertion evidence source_evidence_literature NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
- NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_assertion SIO_000772 17587812 NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
- NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_assertion wasDerivedFrom befree-20150227 NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
- NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_assertion wasGeneratedBy ECO_0000203 NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
- befree-20150227 importedOn "2015-02-27" NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.